Milestone Pharmaceuticals, Inc.’s inhaled calcium channel blocker etripamil already has shown that it can significantly slow patients’ heart rates in a large Phase III clinical trial as a treatment for paroxysmal supraventricular tachycardia (PSVT). Now, the company plans to initiate a Phase III trial in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) after the drug was similarly effective at lowering heart rate in the Phase II ReVeRA study of AFib-RVR patients.
Key Takeaways
-
Milestone reported positive Phase II results for its calcium channel blocker etripamil, administered via nasal spray, as a treatment for atrial fibrillation with rapid ventricular rate (AFib-RVR).
Montreal and Charlotte, NC-based Milestone submitted a new drug application for etripamil in the treatment of PSVT to the US...
Welcome to Scrip
Create an account to read this article
Already a subscriber?